Recent 8-K filings for QNRX

• October 20, 2026, 6:35 AM ET other material materiality 0.45 positive item 7.01item 8.01item 9.01

  Quoin publishes peer-reviewed QRX003 paper; pediatric Netherton case clear at 21 months

  Peer-reviewed paper in Dermatology and Therapy, published online Oct 13, 2026, introduces QRX003 and reports Prof. Alan Irvine's pediatric compassionate-use case.

• October 14, 2026, 6:35 AM ET regulatory materiality 0.55 positive item 7.01item 8.01item 9.01

  Quoin's QRX003 wins EMA Orphan Drug Designation for Peeling Skin Syndrome

  EMA granted Orphan Drug Designation to lead candidate QRX003 for Peeling Skin Syndrome on Oct 14, 2026, giving 10 years of EU market exclusivity if approved.

• September 22, 2026, 4:15 PM ET regulatory materiality 0.60 positive item 7.01item 8.01item 9.01

  FDA grants Fast Track to Quoin's QRX003 for Peeling Skin Syndrome

  FDA granted Fast Track Designation to QRX003 for Peeling Skin Syndrome (PSS) on Sept 22, 2026.

• September 10, 2026, 4:05 PM ET regulatory materiality 0.65 positive item 7.01item 8.01item 9.01

  FDA grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

  Second RPD designation for QRX003; first was for Netherton Syndrome.

• August 28, 2026, 10:31 AM ET other material materiality 0.90 positive item 1.01item 3.02item 7.01item 8.01item 9.01

  Quoin reports positive QRX003 interim data, raises up to $50M in private placement

  Private placement up to $50M: $30.8M upfront at $4.88/ADS+warrant, 6,305,300 ADSs and warrants for 3,152,650 ADSs.

• August 20, 2026, 4:19 PM ET other material materiality 0.30 neutral item 5.02item 5.07item 8.01

  Quoin shareholders approve NED compensation increase to $250k base retainer

  Annual base retainer for non-employee directors increased to up to $250,000, set annually by Compensation Committee.

• August 14, 2026, 4:06 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Quoin Q2 net loss $5.4M; FDA clears first-ever IND for Peeling Skin Syndrome

  Q2 2026 net loss $5.4M vs $3.7M in Q2 2025; six-month loss $10.4M vs $7.5M.

• June 23, 2026, 4:15 PM ET regulatory materiality 0.55 positive item 7.01item 8.01item 9.01

  Quoin Pharma gets FDA conditional approval of brand name QYLEKI for Netherton Syndrome candidate

  FDA conditionally approved QYLEKI as proposed brand name for QRX003, an investigational treatment for Netherton Syndrome.

• June 4, 2026, 4:04 PM ET regulatory materiality 0.60 positive item 7.01item 8.01item 9.01

  Quoin Pharma gets Japan MHLW Orphan Drug Designation for QRX003 in Netherton Syndrome

  Japan MHLW granted Orphan Drug Designation to QRX003 lotion (4%) for Netherton Syndrome, a rare genetic skin disorder with no approved treatments.

• May 7, 2026, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01 ◈ Earnings Releases

  Quoin Q1 net loss $5M; FDA says single Phase 3 may suffice for QRX003

  Net loss $5.0M in Q1 2026 vs $3.8M in Q1 2025; cash $14M expected to fund operations into 2027.

• March 26, 2026, 7:59 PM ET other material materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Quoin raises up to $104.5M, advances QRX003 regulatory path, reports 2025 net loss $15.8M

  Closed private placement for up to $104.5M ($16.5M at closing, $88M warrant potential).

• March 11, 2026, 7:59 PM ET regulatory materiality 0.60 positive item 7.01item 8.01item 9.01

  FDA grants Fast Track Designation to Quoin's QRX003 for Netherton Syndrome

  Fast Track Designation granted to QRX003 lotion (4%) for Netherton Syndrome, a rare genetic skin disorder with no approved treatments.

• January 20, 2026, 6:59 PM ET regulatory materiality 0.60 positive item 7.01item 8.01item 9.01

  Quoin seeks SFDA breakthrough designation; QRX003 could be first approved Netherton treatment in 2H2026

  Filed application with Saudi FDA for Breakthrough Medicine Designation for QRX003 for Netherton Syndrome.

• November 17, 2025, 6:59 PM ET other materiality 0.10 neutral item 5.02item 9.01

  Quoin Pharmaceuticals approves stock option award agreement forms under 2025 Equity Plan

  Compensation Committee approved forms of Incentive and Non-Qualified Stock Option Award Agreements on Nov 14, 2025.

• November 12, 2025, 6:59 PM ET other material materiality 0.60 positive item 7.01item 8.01item 9.01

  Quoin achieves 4% and 5% rapamycin loadings in topical and patch; clinical testing planned H1 2026

  Rapamycin loading 4% w/w in proprietary topical formulation; 5% w/w in dermal patch system.

• November 6, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Quoin Pharma reports Q3 net loss of $3.9M, raises up to $105.3M in private placement

  Net loss of $3.9M for Q3 2025 ($11.5M YTD) vs $2.3M and $6.7M in prior-year periods; R&D spend increased to $2.3M for Q3.

• October 21, 2025, 7:59 PM ET regulatory materiality 0.70 positive item 7.01item 8.01item 9.01

  Quoin Pharmaceuticals receives FDA Orphan Drug Designation for QRX003 in Netherton Syndrome

  FDA grants Orphan Drug Designation to QRX003 for Netherton Syndrome; 7-year US exclusivity if approved.

• October 15, 2025, 7:59 PM ET other material materiality 0.75 positive item 1.01item 3.02item 7.01item 9.01 ◈ Equity Issuances

  Quoin raises $16.6M upfront in PIPE; up to $104.6M total with milestone warrants

  Upfront gross proceeds of $16.6M ($15M net) from private placement; proceeds for QRX003 development and general corporate.

• August 27, 2025, 7:59 PM ET leadership materiality 0.60 neutral item 5.02item 9.01

  Quoin finalizes CFO exit: $433K lieu of notice, $108K bonus, extended options

  Separation agreement signed August 21; effective August 15, 2025.

• August 21, 2025, 7:59 PM ET other material materiality 0.70 neutral item 5.07item 3.03item 5.02item 7.01item 8.01item 9.01

  Quoin shareholders approve increase in shares from 100M to 5B; Sally Lawlor named new CFO

  Shareholders approved amendment to increase authorized ordinary shares from 100,000,000 to 5,000,000,000 (50x).

• August 7, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Quoin Pharma Q2 net loss $3.7M; QRX003 advances with FDA/EMA designations

  Net loss Q2 2025 $3.7M vs $2.0M YoY; cash $7.8M supports operations into Q1 2026.

• July 8, 2025, 7:59 PM ET leadership materiality 0.50 neutral item 5.02

  CFO Gordon Dunn to depart Quoin Pharmaceuticals; will continue until successor named

  Mutual separation agreed on July 3, 2025; CFO Gordon Dunn to leave later this year.

• June 25, 2025, 7:59 PM ET regulatory materiality 0.65 positive item 8.01

  Quoin Pharma receives FDA Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome

  FDA granted Rare Pediatric Disease Designation (RPDD) on June 24, 2025 for QRX003.

• June 20, 2025, 7:59 PM ET other materiality 0.15 neutral item 8.01

  Quoin Pharmaceuticals sets 2025 AGM for August 21; shareholder proposal deadline June 30

  2025 Annual General Meeting scheduled for August 21, 2025.

• June 4, 2025, 7:59 PM ET leadership materiality 0.25 neutral item 5.02

  Quoin Pharma awards CEO $331k and COO $265k in 2024 cash bonuses

  Compensation Committee approved 2024 annual cash bonus of $331,238 for CEO Dr. Michael Myers.

• May 23, 2025, 7:59 PM ET regulatory materiality 0.85 positive item 8.01item 9.01

  Quoin Pharma gets FDA clearance to start second pivotal Netherton Syndrome study for QRX003

  FDA cleared Study CL-QRX003-002, testing whole-body QRX003 (~80% BSA) with off-label systemic therapy in ~12-15 subjects.

• May 21, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  Quoin Pharma gets EMA Orphan Drug Designation for QRX003 for Netherton Syndrome

  EMA grants Orphan Drug Designation for QRX003, a topical treatment for Netherton Syndrome, a rare disease with no approved therapies.

• May 14, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Quoin Pharma Q1 net loss $3.8M; positive QRX003 data and patent expansion

  Cash of $11.6M at March 31, 2025; expected to fund operations into Q1 2026.

• April 30, 2025, 7:59 PM ET regulatory materiality 0.60 positive item 8.01

  Quoin Pharma regains Nasdaq minimum bid price compliance; delisting risk removed

  Received Nasdaq Compliance Notice on April 29, 2025 confirming minimum bid price compliance.

• April 4, 2025, 7:59 PM ET other material materiality 0.60 negative item 3.03

  Quoin Pharma announces 1-for-20 reverse ADS split to regain Nasdaq compliance

  ADS ratio changed from 1:1 to 1:20 (one ADS now represents 20 ordinary shares) effective April 8, 2025.

• April 4, 2025, 7:59 PM ET other material materiality 0.50 neutral item 3.03

  Quoin Pharma approves 1-for-35 reverse ADS split effective April 9 to meet Nasdaq bid price rule

  ADS ratio changes from 1 ADS = 1 ordinary share to 1 ADS = 35 ordinary shares, effective April 9, 2025.

• April 2, 2025, 7:59 PM ET other material materiality 0.70 positive item 8.01

  Quoin Pharma reports positive clinical data for QRX003: skin healed, no adverse events in pediatric Netherton patient

  After 6 weeks of daily whole-body QRX003, the pediatric Netherton patient's skin is almost completely healed.

• March 20, 2025, 7:59 PM ET other material materiality 0.35 neutral item 4.01item 9.01 ◈ Auditor Changes ×2

  Quoin Pharmaceuticals replaces auditor Marcum LLP with CBIZ CPAs after attest business acquisition

  Marcum LLP resigned as auditor on March 18, 2025; CBIZ CPAs P.C. engaged effective immediately for FY 2025.

• March 13, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Quoin reports FY2024 net loss $9.0M; cash $14.1M; positive QRX003 whole-body data in Netherton

  Cash of $14.1M at Dec 31, 2024 expected to fund operations into Q2 2026.

• February 27, 2025, 6:59 PM ET other material materiality 0.75 positive item 8.01

  Quoin Pharma: pediatric Netherton Syndrome patient shows dramatic skin healing after 2 weeks of QRX003

  IGA score improved from 7 to 1-2 (0-10 scale) after two weeks of whole-body QRX003 treatment.

• February 4, 2025, 6:59 PM ET other material materiality 0.20 positive item 8.01

  Quoin launches Netherton NOW campaign for rare disease awareness

  Campaign 'NETHERTON NOW' launched Feb 4, 2025 to raise awareness for Netherton Syndrome.

• January 23, 2025, 6:59 PM ET other material materiality 0.55 neutral item 8.01

  Quoin reports reversal of QRX003 benefits 4 weeks post-discontinuation in Netherton syndrome study

  M-IASI score returned from 3 (12 weeks) to 18 at 4 weeks post-discontinuation, equaling baseline of 18.

• January 16, 2025, 6:59 PM ET other material materiality 0.65 positive item 8.01

  Quoin reports positive QRX003 data in Netherton Syndrome: IGA improves from severe to mild after 6 weeks

  IGA score improved from 'severe' at baseline to 'mild' after six weeks of twice-daily QRX003 dosing.

• January 6, 2025, 6:59 PM ET other material materiality 0.75 positive item 8.01

  Quoin reports Netherton Syndrome patient achieves near-clear skin after 12 weeks of QRX003 twice-daily

  M-IASI score improved from 18 to 3; WINRS from 7 to 2; IGA from Moderate to Almost Clear after 12 weeks.

• December 26, 2024, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 8.01item 9.01

  Quoin Pharmaceuticals prices $6.8M public offering of ADSs and warrants

  Gross proceeds ~$6.8M from offering of 15,111,110 ADSs (or pre-funded warrants) and Series F/G warrants at $0.45 per unit.

• December 19, 2024, 6:59 PM ET other material materiality 0.70 positive item 8.01

  Quoin Pharma gets FDA clearance for whole-body QRX003 study in Netherton Syndrome

  FDA clearance for new Netherton Syndrome study of QRX003 applied to >80% BSA twice daily for 12 weeks in up to 8 patients.

• December 10, 2024, 6:59 PM ET other material materiality 0.50 neutral item 3.03item 5.02item 5.07item 8.01item 9.01

  Quoin shareholders approve charter amendments and executive compensation; board grants options

  Shareholders approved amendments to Articles reducing quorum to 33 1/3% (25% for foreign private issuers) and aligning special meeting provisions.

• November 8, 2024, 6:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Quoin Q3 net loss $2.3M; initiates Peeling Skin Syndrome study; management buys shares

  Net loss of $2.3M for Q3 2024 vs $1.9M in Q3 2023; nine-month net loss $6.7M vs $6.6M.

• October 31, 2024, 7:59 PM ET other material materiality 0.40 neutral item 3.01

  Quoin Pharma gets Nasdaq bid-price extension to April 28, 2025

  Nasdaq granted additional 180-day grace period until April 28, 2025 to regain $1.00 minimum bid price compliance.

• September 30, 2024, 7:59 PM ET other materiality 0.10 neutral item 5.08item 8.01

  Quoin Pharma sets 2024 AGM for Dec 5; shareholder proposals due Oct 10

  Annual meeting scheduled for December 5, 2024, more than 30 days after last year's anniversary.

• August 14, 2024, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  Quoin posts Q2 net loss of $2.0M; cash $12.6M; expands Netherton trials internationally

  Cash, cash equivalents and marketable securities of $12.6M as of June 30, 2024; expected to fund operations into late 2025.

• May 3, 2024, 7:59 PM ET regulatory materiality 0.50 negative item 3.01 ◈ Listing & Compliance Notices

  Quoin Pharma receives Nasdaq notice for non-compliance with $1.00 minimum bid price

  Received Nasdaq notice on April 29, 2024 for failing to maintain minimum bid price of $1.00 per ADS for 31 consecutive business days through April 26, 2024.

• April 9, 2024, 7:59 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes

  Quoin shareholders approve issuance of shares to Alumni Capital LP

  Special meeting on April 5, 2024 approved Alumni Issuance Proposal.

• March 13, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Quoin Pharma reports Q4/FY2023 net loss $8.7M; cash runway to H2 2025; positive QRX003 data

  Net loss Q4 2023 $2.0M (flat YoY); FY2023 $8.7M vs $9.4M in 2022.

• March 8, 2024, 6:59 PM ET other material materiality 0.75 positive item 1.01item 8.01item 9.01 ◈ Material Agreements

  Quoin Pharma raises $6.5M via public offering; FDA clears teen enrollment in Netherton Syndrome trials

  Raised $6.5M gross from public offering of ADSs, pre-funded and Series D/E warrants at $1.60 combined per unit.

Materiality & sentiment trend

Max materiality 0.90 · Median 0.60 · Most common event other_material

30 positive 2 negative 18 neutral

source · QNRX on sec.gov